. . "2"^^ . "2"^^ . . "Nowadays there is no reliable possibility for BE patients to predict risk of progression to adenocarcinoma (EAC). Proposed project aims finding of new diagnostic and predictive markers (miRNA based diagnostic panel). Particular miRNA expression analysis will enable the histopathological diagnostics refinement (dysplastic grade and early detection of progression into HGD and EAC). This statement is based on fact that molecular-genetic examinations are very sensitive and are not influenced by variability of histopathological sample subjective evaluation. MiRNA based diagnostic panel will further enable stratification of BE patients to subgroups according to their individual risk of progression to EAC, particularly it will enable the \u201Ehigh-risk\u201C subgroups detection. More accurate risk prediction in BE patients enable more rationalized monitoring design and early detection of progression to higher dysplastic grade or EAC."@en . "1"^^ . . "1"^^ . . "2013-03-26+01:00"^^ . "NT13585" . . . . "Barrett\u00B4s Esophagus" . . " Adenocarcinoma" . . . "2014-12-31+01:00"^^ . "Development of microRNA diagnostic panel for identification Barret esophagus patients at high-risk of progression to adenocarcinoma"@en . "2012-04-01+02:00"^^ . "2015-01-22+01:00"^^ . . . "Barrett\u00B4s Esophagus; Adenocarcinoma; miRNA"@en . . "http://www.isvav.cz/projectDetail.do?rowId=NT13585"^^ . . . "Vytvo\u0159en\u00ED diagnostick\u00E9ho panelu mikroRNA pro identifikaci podskupiny pacient\u016F s Barretov\u00FDm j\u00EDcnem s vysok\u00FDm rizikem progrese do karcinomu" . "V sou\u010Dasn\u00E9 dob\u011B pro pacienty s BE neexistuje mo\u017Enost spolehliv\u00E9 predikce rizika progrese do EAC. P\u0159edkl\u00E1dan\u00FD projekt sm\u011B\u0159uje k nalezen\u00ED nov\u00FDch diagnostick\u00FDch a prediktivn\u00EDch marker\u016F (diagnostick\u00E9ho panelu miRNA). Anal\u00FDza exprese vybran\u00FDch miRNA (diagnostick\u00FD panel) umo\u017En\u00ED zp\u0159esn\u011Bn\u00ED histopatologick\u00E9 diagnostiky (stupn\u011B dyspl\u00E1zie a \u010Dasn\u00E9ho z\u00E1chytu progrese do HGD a EAC) pacient\u016F s BE, p\u0159edev\u0161\u00EDm t\u00EDm, \u017Ee molekul\u00E1rn\u011B-genetick\u00E1 vy\u0161et\u0159en\u00ED nejsou zat\u00ED\u017Eena variabilitou danou subjektivn\u00EDm hodnocen\u00EDm histopatologick\u00E9ho n\u00E1lezu, a vykazuj\u00ED vy\u0161\u0161\u00ED m\u00EDru senzitivity. Diagnostick\u00FD panel miRNA d\u00E1le umo\u017En\u00ED stratifikaci pacient\u016F s BE do skupin dle rizika progrese do EAC, konkr\u00E9tn\u011B umo\u017En\u00ED nal\u00E9zt tzv. \u201Ehigh-risk\u201C podskupinu. P\u0159esn\u011Bj\u0161\u00ED predikce rizika u pacient\u016F s BE umo\u017En\u00ED racion\u00E1ln\u011Bj\u0161\u00ED nastaven\u00ED programu jejich sledov\u00E1n\u00ED, a n\u00E1sledn\u011B tak\u00E9 \u010Dasn\u011Bj\u0161\u00ED z\u00E1chyt progrese do vy\u0161\u0161\u00EDho stupn\u011B dysplazie a EAC." . "0"^^ . .